A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL)

A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL)

Background: ZOSTAVAX (ZVL; Zoster Virus Live), is a single dose, live, attenuated vaccine licensed for the prevention of herpes zoster (HZ) and post herpetic neuralgia (PHN) in adults ≥50 years of age. Injection site adverse events (AEs) of erythema, swelling and pain were solicited within 5 days po...

Full description

Bibliographic Details
Main Authors: Zoran Popmihajlov, Lei Pang, Elizabeth Brown, Amita Joshi, Shu-Chih Su, Susan S. Kaplan, English D. Willis
Format: Article
Language:English
Published: Taylor & Francis Group 2018-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
herpes zoster
shingles
zoster vaccine
severe adverse events
safety
Online Access:http://dx.doi.org/10.1080/21645515.2018.1502517

Similar Items

Similar Items